Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
about
Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cellsSystematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.The evolution of clinical trials for infant acute lymphoblastic leukemia.Comparison of in vitro antileukemic activity of obatoclax and ABT-737.Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.Dysregulation of BCL-2 family proteins by leukemia fusion genes.Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy.Development of β-cyclodextrin-based sustained release microparticles for oral insulin delivery.
P2860
Q28484487-9EDF257E-B8B0-42A3-BB19-E7507DD63AADQ34031153-388CC567-741F-46B2-BE4E-D0950CB97324Q35251905-FE86F205-C8B0-4CED-B30E-950FAD768580Q35553586-0B849C20-5A3F-4038-95BE-6E2AD2ADCD38Q36056038-DC0E614C-92DB-4015-B22B-7311FF0BB875Q37330840-434203D5-3603-4722-BB40-44CBD9F2C0AFQ37730023-2E9DAF77-B8EC-46EE-BCF3-976FF277D6DFQ38793940-0F107435-16C6-46B1-B4D8-30B626A07FE0Q39240059-5121E795-310C-4FC8-ADF9-2BB63A78308EQ39440247-20B8AD9C-73A9-400E-B2F9-16AA57BF971DQ53272796-FD99204D-407E-4C69-B50A-89AA12B1D133Q53465156-45A1D331-35A0-45B2-BF52-8E27C01C4356
P2860
Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@en
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@nl
type
label
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@en
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@nl
prefLabel
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@en
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@nl
P2093
P2860
P356
P1476
Cytotoxicity, drug combinabili ...... cells with MLL rearrangement.
@en
P2093
Aarthi Jayanthan
Andrea Incoronato
Anjali Singh
Aru Narendran
Christopher Blackmore
Delphine Bernoux
James A Whitlock
Ronald Stam
Victor Lewis
P2860
P304
P356
10.1002/PBC.22760
P577
2010-11-28T00:00:00Z